Study S002183

Effect of Injection Site on the Relative Bioavailability of a Single Dose of LY3437943 in Healthy Participants With a High Body Mass Index

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05959096
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 85
Start: 2023-07-18
Primary completion: 2024-07-25
Lead sponsor: Eli Lilly and Company
Conditions: Healthy
Interventions: DRUG:LY3437943
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER:J1I-MC-GZBS

Registered primary outcomes

Part A: Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3437943 [Predose on Day 1 up to 43 days postdose (Part A)]
Part A: PK: Maximum Concentration (Cmax) of LY3437943 [Predose on Day 1 up to 43 days postdose (Part A)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.